Artiva Biotherapeutics’ (ARTV) Buy Rating Reiterated at HC Wainwright

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 401.25% from the company’s previous close.

A number of other equities research analysts have also issued reports on ARTV. Wedbush reissued an “outperform” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Tuesday. Cantor Fitzgerald decreased their target price on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday. Finally, Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a report on Tuesday. Six analysts have rated the stock with a buy rating, According to MarketBeat, Artiva Biotherapeutics currently has a consensus rating of “Buy” and a consensus price target of $20.40.

Artiva Biotherapeutics Trading Up 2.0 %

Shares of NASDAQ:ARTV opened at $3.99 on Wednesday. Artiva Biotherapeutics has a 12 month low of $3.37 and a 12 month high of $17.31. The firm’s 50-day moving average is $4.91 and its 200 day moving average is $9.37.

Hedge Funds Weigh In On Artiva Biotherapeutics

Institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new position in Artiva Biotherapeutics during the 3rd quarter worth about $42,000. Charles Schwab Investment Management Inc. lifted its position in shares of Artiva Biotherapeutics by 8.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock worth $439,000 after purchasing an additional 3,233 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after purchasing an additional 3,361 shares in the last quarter. Northern Trust Corp increased its holdings in Artiva Biotherapeutics by 3.8% during the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock valued at $1,180,000 after buying an additional 4,335 shares during the period. Finally, Barclays PLC raised its stake in Artiva Biotherapeutics by 23.2% in the fourth quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after buying an additional 4,545 shares in the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.